Loading clinical trials...
Loading clinical trials...
Molecular Taxonomy of Pediatric Cancer
This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
OBJECTIVES: I. To identify global changes in the epigenome and various underlying histone modifications that characterize relapsed acute lymphoblastic leukemia (ALL). II. To identify specific transcription factor-binding sites associated with histone alterations. III. To correlate gene expression changes of differentially regulated genes at relapse with underlying chromatin modifications. OUTLINE: Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
Age
0 - 21 years
Sex
ALL
Healthy Volunteers
No
Children's Oncology Group
Arcadia, California, United States
Start Date
June 1, 2012
Primary Completion Date
May 1, 2016
Last Updated
May 18, 2016
40
ESTIMATED participants
laboratory biomarker analysis
OTHER
Lead Sponsor
Children's Oncology Group
Collaborators
NCT02220985
NCT00381680
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions